IRBESARTIN IN HYPERTENSIVE PATIENTS W/ TYPE II DIABETES

$0M01FY2000RRNIH

Medical College Of Wisconsin, Milwaukee WI

Investigators

Linked publications & trials

Paper 37403287 Paper 37190038 Paper 34998799 Paper 34904226 Paper 32131913 Paper 31161655 Paper 30242573 Paper 29568273 Paper 28437659 Paper 27903333 Paper 27834774 Paper 27656016 Paper 26974186 Paper 26339656 Paper 25915144 Paper 25863238 Paper 25750259 Paper 25687593 Paper 25442065 Paper 24905283 Paper 24795624 Paper 24315840 Paper 24141988 Paper 23936625 Paper 23829951 Paper 23688215 Paper 23669872 Paper 23541860 Paper 23539320 Paper 23528339 Paper 23418049 Paper 23389889 Paper 23294162 Paper 23221862 Paper 23199565 Paper 22879582 Paper 22494468 Paper 22421106 Paper 22272622 Paper 22120494 Paper 22102362 Paper 21996618 Paper 21932265 Paper 21840405 Paper 21812992 Paper 21769962 Paper 21715240 Paper 21601432 Paper 21435573 Paper 21358502 Paper 21289230 Paper 21252216 Paper 21251283 Paper 21248238 Paper 21160464 Paper 21151941 Paper 21106659 Paper 20850386 Paper 20849805 Paper 20846700 Paper 20691792 Paper 20634590 Paper 20629578 Paper 20589646 Paper 20454695 Paper 20382643 Paper 20229888 Paper 20178797 Paper 20167415 Paper 20140963 Paper 20096790 Paper 20067342 Paper 19921648 Paper 19880277 Paper 19834399 Paper 19817807 Paper 19801018 Paper 19778958 Paper 19763119 Paper 19741317 Paper 19711398 Paper 19704080 Paper 19670416 Paper 19654878 Paper 19549721 Paper 19546154 Paper 19515831 Paper 19371442 Paper 19302424 Paper 19295543 Paper 19171643 Paper 19151694 Paper 19128524 Paper 19120444 Paper 19036100 Paper 18989755 Paper 18929686 Paper 18927004 Paper 18798333 Paper 18780827

Abstract

This project will test the efficacy of irbesartin in reducing the rate of progression of renal disease and cardiovascular events in hypertensive patients with diabetic nephropathy due to type II diabetes compared to patients treated with the calcium channel antagonist amlodipine or placebo.

View original record on NIH RePORTER →